Literature DB >> 30086574

Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.

Susan A Maroney1, Julie A Peterson1, Wes Zwifelhofer1, Nicholas D Martinez1, Ke Yan2, Rachel S Bercovitz1,2,3, Ronald K Woods4,5, Alan E Mast1,6.   

Abstract

BACKGROUND: Neonates undergoing cardiopulmonary bypass (CPB) surgery to correct congenital heart defects often experience excessive bleeding. Exposure of blood to artificial materials during CPB may activate coagulation, complement and inflammatory pathways. In addition, the surgical stress placed on the haemostatic system may result in cross-activation of other plasma proteolytic cascades, which could further complicate physiological responses to the surgical procedure and post-operative recovery. Plasma protease inhibitors undergo distinct conformational changes upon interaction with proteases, and, thereby, can serve as endogenous biosensors to identify activation of the different proteolytic cascades. We tested the hypothesis that changes in the concentration and conformation of protease inhibitors regulating plasma proteolytic cascades during neonatal CPB are associated with post-operative bleeding. PATIENTS AND METHODS: Plasma samples from 44 neonates were obtained at four time points across the surgical procedure. Anti-thrombin, antitrypsin, anti-chymotrypsin, anti-plasmin, C1-inhibitor and tissue factor pathway inhibitor (TFPI) concentrations and conformations were evaluated by enzyme-linked immunosorbent assay, transverse urea gradient gel electrophoresis and sodium dodecyl sulphate-polyacrylamide gel electrophoresis. RESULTS/
CONCLUSION: The most striking changes were observed following heparin administration and were associated with the appearance of inactive forms of anti-thrombin and an increase in the plasma concentration of TFPI. Changes in anti-thrombin and TFPI remained evident throughout surgery and into the post-operative period but were not different between patients with or without post-operative bleeding. The concentration of antitrypsin decreased across surgery, but there was no significant accumulation of inactive conformations of any inhibitor besides anti-thrombin, indicating that widespread cross-activation of other plasma proteolytic cascades by coagulation proteases did not occur. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30086574      PMCID: PMC6138520          DOI: 10.1055/s-0038-1667198

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  43 in total

Review 1.  Activation of the hemostatic system during cardiopulmonary bypass.

Authors:  Roman M Sniecinski; Wayne L Chandler
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

2.  Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.

Authors:  W F Novotny; M Palmier; T C Wun; G J Broze; J P Miletich
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

Review 3.  Developmental hemostasis: primary hemostasis and evaluation of platelet function in neonates.

Authors:  T Strauss; R Sidlik-Muskatel; G Kenet
Journal:  Semin Fetal Neonatal Med       Date:  2011-07-31       Impact factor: 3.926

4.  Complement and contact activation during cardiovascular operations in infants.

Authors:  J Sonntag; I Dähnert; B Stiller; R Hetzer; P E Lange
Journal:  Ann Thorac Surg       Date:  1998-02       Impact factor: 4.330

5.  Anticoagulant action of heparin.

Authors:  P S Damus; M Hicks; R D Rosenberg
Journal:  Nature       Date:  1973-12-07       Impact factor: 49.962

6.  Development of the human coagulation system in the full-term infant.

Authors:  M Andrew; B Paes; R Milner; M Johnston; L Mitchell; D M Tollefsen; P Powers
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

7.  Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children.

Authors:  Nathalie Hézard; Gérard Potron; Nicole Schlegel; Catherine Amory; Bernard Leroux; Philippe Nguyen
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

8.  Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn.

Authors:  J F Cade; J Hirsh; M Martin
Journal:  Br Med J       Date:  1969-05-03

9.  Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.

Authors:  L V Rao; S I Rapaport
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

10.  Validation of a definition of excessive postoperative bleeding in infants undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Rachel S Bercovitz; Allison C Shewmake; Debra K Newman; Robert A Niebler; John P Scott; Eckehard Stuth; Pippa M Simpson; Ke Yan; Ronald K Woods
Journal:  J Thorac Cardiovasc Surg       Date:  2017-12-13       Impact factor: 5.209

View more
  4 in total

Review 1.  Developmental hemostasis in the neonatal period.

Authors:  Vicente Rey Y Formoso; Ricardo Barreto Mota; Henrique Soares
Journal:  World J Pediatr       Date:  2022-01-04       Impact factor: 2.764

2.  Factor V east Texas variant causes bleeding in a three-generation family.

Authors:  Julie A Peterson; Sweta Gupta; Nicholas D Martinez; Brandon Hardesty; Susan A Maroney; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-12-07       Impact factor: 5.824

3.  Platelet Function Changes during Neonatal Cardiopulmonary Bypass Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding.

Authors:  Nicole M J Zwifelhofer; Rachel S Bercovitz; Regina Cole; Ke Yan; Pippa M Simpson; Alyssa Moroi; Peter J Newman; Robert A Niebler; John P Scott; Eckehard A D Stuth; Ronald K Woods; D Woodrow Benson; Debra K Newman
Journal:  Thromb Haemost       Date:  2019-11-21       Impact factor: 5.249

4.  Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.

Authors:  Julie A Peterson; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-08       Impact factor: 10.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.